The night blindness treatment market has seen considerable growth due to a variety of factors.
• The night blindness treatment market has expanded considerably in recent years. It is projected to grow from $3.95 billion in 2024 to $4.21 billion in 2025, at a compound annual growth rate (CAGR) of 6.7%.
This growth is driven by the rising prevalence of vitamin A deficiency, a growing aging population prone to night vision issues, the expansion of healthcare infrastructure, greater focus on nutritional interventions, and increasing cases of retinitis pigmentosa.
The night blindness treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The night blindness treatment market is projected to grow significantly, reaching $5.39 billion by 2029 with a CAGR of 6.3%.
This growth is fueled by the adoption of advanced diagnostic technologies, awareness campaigns about eye health, a rise in personalized medicine demand, the growth of eye care clinics, and healthcare infrastructure development. Key trends include the use of advanced diagnostic tools, personalized treatment approaches, gene therapy and stem cell developments, wearable technology for real-time monitoring, and multi-disciplinary clinic growth.
The increasing prevalence of cataracts is expected to drive the growth of the night blindness treatment market. Cataracts cloud the eye’s lens, impairing vision and leading to difficulties seeing in low light. Contributing factors include excessive sun exposure, smoking, and poor diet. Night blindness, which results from cataracts, affects the ability to navigate in the dark. For example, in July 2023, the UK National Eye Care Statistics Survey reported a 23.7% increase in cataract admissions from the previous year, indicating a rise in cataract-related night blindness cases.
The night blindness treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Diagnosis: Blood Tests, Color Vision Testing, Pupil Light Reflex, Refraction, Retinal Exam, Electroretinogram (ERG), Other Diagnoses
3) By Symptom: Eye Pain, Vomiting, Cloudy Vision, Halos, Light Sensitivity, Distance Vision Problem, Headache, Other Symptoms
4) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Medication: Vitamin A Supplements, Retinoid Therapy, Beta-Carotene Supplements, Anti-Glaucoma Medications, Other Pharmaceutical Treatments
2) By Surgery: Cataract Surgery, Retinal Surgery, Corneal Transplantation, LASIK Surgery
3) By Other Treatments: Light Therapy, Gene Therapy, Low Vision Aids And Assistive Devices, Nutritional Therapy
In the night blindness treatment market, leading corporations are pioneering novel genetic treatments which target the root genetic mutations enhancing treatment success for better patient health results. These genetic remedies provide a solution to night blindness by pinpointing and rectifying particular genetic mutations impacting retinal operations, potentially reviving vision in people possessing inherited retinal disorders, for example, retinitis pigmentosa. HuidaGene Therapeutics, a clinical-phase biotech firm based in the US, launched HG004, a gene remedy aimed at curing inherited retinal diseases such as Leber's congenital amaurosis, in August 2023. This treatment has demonstrated superiority against existing treatments in pre-clinical investigations, with objectives to regain retinal operations and mitigate night blindness and other RPE65-induced conditions.
Major companies operating in the night blindness treatment market are:
• Johnson & Johnson Private Limited
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Abbott Laboratories
• Novartis AG
• Boehringer Ingelheim
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Eisai Co. Ltd
• Cipla Inc.
• Nature's Way
• Spark Therapeutics Inc.
• Garden of Life
• Apellis Pharmaceuticals Inc
• Solgar
• Acucela Inc.
• Swanson Health Products
• NOW Foods
North America was the largest region in the night blindness treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the night blindness treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.